This issue of Grand Rounds in Urology reviews the current and future use of ADT in treating advanced prostate cancer, but with cost of healthcare an ever growing factor in treatment decisions, it will also examine the potential use of older antiandrogen therapies in treating patients with advanced PCa.
Presentation
Keywords
prostate carcinoma, antiandrogens
Faculty
Medical Editor:
E. David Crawford, MD
Professor of Surgery, Urology, and Radiation Oncology Head, Urologic Oncology
E. David Crawford Endowed Chair in Urologic Oncology
University of Colorado, Denver
Aurora, Colorado
Faculty:
Gerald L. Andriole, Jr., MD
Robert Killian Royce Distinguished Professor
Professor, Surgery Chief, Division of Urologic Surgery
Director, Men’s Health Center
St. Louis, Missouri
Raoul S. Concepcion, MD
Director of Advanced Therapeutics
Urology Associates, Nashville
Nashville, Tennessee
Robert E. Donohue, MD
Professor Emeritus
University of Colorado, Denver
Aurora, Colorado
Leonard G. Gomella, MD
Bernard W. Godwin Jr. Professor of Prostate Cancer
Chairman Department of Urology
Thomas Jefferson University
Philadelphia, Pennsylvania
Daniel P. Petrylak, MD
Director of Genitourinary Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut
J. Clifton Vestal, MD
Urologist
USMD Prostate Cancer Center
USMD Health System
Arlington, Texas
References
References
Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001;58(6):1016-20.
Du Plessis DJ. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology. 1991;37(2 Suppl):20-4.
Fisher LD, Gent M, Büller HR. Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. American Heart Journal. 2001;141(1):26–32
Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4.
Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. The Lancet. 1995;346(8970):265–9. [No Authors Listed]
Rothmann M, Li N, Chen G, Chi GYH, Temple R, Tsou H-H. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine. 2002;22(2):239–64.
Schellhammer PF, Sharifi R, Block NL, et al. Nical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology. 1997;50(3):330–6.
Sun M, Choueiri TK, O-P R Hamnvik, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016;2(4):500-7.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone- Sensitive Prostate Cancer. N Engl J 2015;373:737-46.
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
He is currently a Professor of Urology at the University of California, San Diego, and emeritus distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians.
In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC.
Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.
Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.
